BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32042586)

  • 1.
    Ogasawara T; Kawauchi K; Ono T; Marshall S; Shide K; Shimoda K; Mori N; Sakura H
    Leuk Res Rep; 2020; 13():100194. PubMed ID: 32042586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm.
    Sato S; Itonaga H; Taguchi M; Sawayama Y; Imanishi D; Tsushima H; Hata T; Moriuchi Y; Mishima H; Kinoshita A; Yoshiura KI; Miyazaki Y
    Int J Hematol; 2018 Aug; 108(2):213-217. PubMed ID: 29417354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TET2, DNMT3A, IDH1, and JAK2 Mutation in Myeloproliferative Neoplasms in southern Iran.
    Abedi E; Ramzi M; Karimi M; Yaghobi R; Mohammadi H; Bayat E; Moghadam M; Farokhian F; Dehghani M; Golafshan HA; Haghpanah S
    Int J Organ Transplant Med; 2021; 12(3):12-20. PubMed ID: 35509721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.
    Ayad MW; Nafea D
    Genet Test Mol Biomarkers; 2011; 15(1-2):17-21. PubMed ID: 21034166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
    Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
    Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
    Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of the JAK2 gene mutation in familial myeloproliferative neoplasm and its clinical significance].
    Zhang YM; Hao LX; Wei Q; Wei YQ; Huang F; Zhang Y; Yin CX; Feng R
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):103-7. PubMed ID: 22730657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Polycythemia Vera Evolve from Acute Myeloid Leukemia? Report of a Case Showing a Simultaneous Minor
    Borsellino B; Savi A; Pascale MR; Meddi E; Del Principe MI; Cristiano A; Ottone T; Rapanotti MC; Divona M; Travaglini S; Attardi E; Palmieri R; Buzzatti E; Buccisano F; Voso MT
    Mediterr J Hematol Infect Dis; 2022; 14(1):e2022058. PubMed ID: 35865394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New advances in the pathogenesis and therapy of essential thrombocythemia.
    Levine RL; Heaney M
    Hematology Am Soc Hematol Educ Program; 2008; ():76-82. PubMed ID: 19074062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
    He ZP; Tian HY; Tan M; Wu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
    Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms.
    Haybar H; Khodadi E; Shahjahani M; Saki N
    Cardiovasc Hematol Disord Drug Targets; 2017; 17(3):161-166. PubMed ID: 29086702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated ten-eleven translocation 2 positive in triple negative essential thrombocythemia: Case report and literature review.
    Al-Ansari RY; Al Otaibi D; Al Hudaithi N; Abdalla L
    SAGE Open Med Case Rep; 2021; 9():2050313X211032066. PubMed ID: 34350001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm.
    Herborg LL; Nederby L; Kjeldsen E; Grønbæk K; Hokland P; Hansen M; Celik Hansen M; Roug AS
    Leuk Res Rep; 2013; 2(2):51-3. PubMed ID: 24371780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor Cells.
    Pearson S; Blance R; Somervaille TCP; Whetton AD; Pierce A
    Hemasphere; 2019 Jun; 3(3):e233. PubMed ID: 31723838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.